NASHUA, N.H., Nov 09, 2011 (BUSINESS WIRE) -- iCAD, Inc. ICAD -1.59% , an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that its Xoft Axxent(R) eBx(TM) electronic brachytherapy system for intraoperative radiation therapy (IORT) has been recently adopted at leading hospitals across the country. Facilities that have chosen the Xoft Axxent eBx System for IORT include Diablo Valley Oncology/Hematology (Pleasant Hill, Calif.), Exeter Hospital (Exeter, N.H.), Memorial Hospital Chattanooga (Chattanooga, Tenn.), Florida Hospital Tampa (Tampa, Fla.), Rockford Memorial Hospital (Rockford, Ill.), Rose Medical Center (Denver, Colo.) and Vanderbilt Medical Center (Nashville, Tenn.)
"The recent adoption of the Axxent eBx System is an increasing endorsement of electronic brachytherapy and IORT as a safe and effective method of radiation treatment," said Ken Ferry, President and CEO of iCAD. "The growing demand for IORT offers patients expanded access to potentially lifesaving radiation therapy for their cancer treatment and an alternative to long-term radiation therapy."
IORT enables doctors to administer a high dose of radiation to the tumor bed during a lumpectomy, which reduces or eliminates the need for follow-up radiation treatments and also minimizes radiation exposure to healthy tissue and organs, such as the ribs, lungs, heart and opposite breast. The current standard of care for early stage breast cancer consists of lumpectomy, medical therapy, and a five to seven week course of daily Whole Breast External Beam Radiation Therapy (WBEBRT) delivered by linear accelerators inside a heavily shielded room. With IORT, a single dose of intraoperative radiation may be as effective in treating the tumor as 10--20 daily radiation doses.(1)
source: Business Wire
Sunday, November 13, 2011
iCAD Announces Recent Adoption of Its Xoft Electronic Brachytherapy System by Leading U. S. Hospitals
Posted by Rad at 11:18 AM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment